Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study

By sjmartinez • July 19, 2023

Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, Chen Y, Rao N, Denis L, Gupta S. Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study. J Am Acad Dermatol. 2023 Aug;89(2):235-242. doi: 10.1016/j.jaad.2023.04.027. Epub 2023 Apr 23. PMID: 37094653.

Tags: Chronic Hand Eczema, Dermatology, Janus kinase inhibitor, modified total lesion-symptom score, Olive View DoM, Physician Global Assessment, Publications, Spleen Kinase Inhibitor

Brodalumab: 5-Year US Pharmacovigilance Report

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Martin GM, Rawnsley NN, Goehring EL Jr, Jacobson AA. Brodalumab: 5-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb).[...]

TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial

Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy[...]

Assessing GPT-4’s Diagnostic Accuracy with Darker Skin Tones: Underperformance and Implications

Akuffo-Addo E, Samman L, Munawar L, Akbik M, Kokikian N, Wescott R, Wu JJ. Assessing GPT-4's Diagnostic Accuracy with Darker Skin Tones: Underperformance and Implications.[...]